AZ Oncology India — 360° Intelligence Hub

Secondary Sales — Apr

₹18.4 Cr

Trade channel MTD

↑ 13% MoM

PAP Enrolled

2,841

↑ 141 MoM

New Initiations

214

↑ 3% MoM

Tagrisso Mkt Share

42%

↑ 4pp YoY

IB Revenue YTD

₹8.4 Cr

↑ 16% YoY

PAP Programme

Patient access · Apr 2025

Tagrisso

1,624

active patients

Enhertu

1,217

active patients

Initiation trend — Nov to Apr

Adherence

78%

Avg Cycles

8.2

At Risk

187

HCP Analytics

Field performance · Apr 2025

Total HCPs

1,247

8 territories

Active Rx

418

last 30 days

NBRX trend — Nov to Apr

Tier 1

186

Dormant

203

Top 10% →

58%

Distribution

Secondary & supply · Apr 2025

Secondary

₹18.4 Cr

Apr MTD

May Fcst

₹20.1 Cr

↑ 9% projected

Secondary trend — Nov to Apr

Critical

1

Low Stock

2

Distributors

48

Market Intelligence

IPSOS · Q1 2025

Tagrisso (NSCLC)42%

↑ 4pp YoY · 8pp above market growth rate

Enhertu (HER2+)28%

↑ 17pp above market growth rate

YoY Growth vs Market

+22%

Tagrisso

+31%

Enhertu

+14%

Market

IB Performance

Institutional channel · YTD

TG IB Rx

1,942

↑ 16% YoY

ENH IB Rx

1,342

↑ 28% YoY

6M Waterfall Forecast

Apr → Oct 2025

₹24.8 Cr

from ₹18.4 Cr baseline

Accounts

84

New QTD

7

Declining

5

Top Accounts

Customer 360 · Rx momentum

AH

Apollo Hospitals, Mumbai

186 Rx YTD · Both brands

↑ 18%

TM

Tata Memorial Centre, Mumbai

162 Rx YTD · Both brands

↑ 14%

AI

AIIMS, Delhi

148 Rx YTD · Both brands

↑ 9%

RG

Rajiv Gandhi Cancer Institute

124 Rx YTD · Tagrisso only

↑ 5%

YH

Yashoda Hospital, Hyderabad

96 Rx YTD · Tagrisso only

↓ –12%

Total HCPs

1,247

Across 8 territories

Tier 1 Doctors

186

↑ 12 this month

Active Prescribers

418

Rx in last 30 days

Dormant HCPs

203

No Rx in 60+ days

NBRX Trend — last 6 months

Combined brands

Tagrisso

Enhertu

HCP Tier Distribution

By prescribing volume — YTD

Tier 1186

Tier 2418

Tier 3643

HCP Performance Table

Sorted by NBRX YTD

HCP	Territory	Tier	Tagrisso Rx	Enhertu Rx	Last Rx	Status	Action
Dr. Priya Mehta	Mumbai North	Tier 1	22	20	Apr 10	Both	↑ +18%
Dr. Arjun Kapoor	Delhi NCR	Tier 1	35	0	Apr 2	Tagrisso	Flat
Dr. Rahul Sharma	Hyderabad	Tier 2	12	14	Mar 28	Both	↑ +9%
Dr. Kavitha Nair	Chennai	Tier 3	8	6	Mar 22	Both	↓ –5%

PM

Dr. Priya Mehta

Both BrandsTier 1

Medical Oncologist · Sir H.N. Reliance Foundation Hospital, Mumbai

NSCLCHER2+ BreastGastric/GEJ ZBM: Sneha Patil · Territory: Mumbai North · HCP-00341

Total NBRX (YTD)

42

First Tagrisso Rx

Jan 12, 2024

First Enhertu Rx

Aug 5, 2024

Program Enrolments

7 patients

Avg Rx Frequency

18 days

Dropout Rate

14%

Rx Volume Trend

Monthly NBRX · both brands

Tagrisso

Enhertu

Rx by Indication

YTD prescription split

NSCLC (Tagrisso)

22 52%

HER2+ Breast (Enhertu)

14 33%

Gastric/GEJ (Enhertu)

6 15%

Prescribing Frequency

Time between repeat orders

Avg gap (Tagrisso)

16d

Avg gap (Enhertu)

22d

Longest gap seen

41d

Orders this month

6

New vs Continuation Rx

Patient type split — YTD

New patients

26

62% of total Rx

Continuation Rx

16

38% of total Rx

Split by brand

Tagrisso

67%

33%

Enhertu

50%

Patient Dropout Rate

Discontinuation by indication

14%

Overall YTD dropout

Tagrisso — NSCLC 1st line8%

Tagrisso — NSCLC 2nd line22%

Enhertu — HER2+ Breast18%

Enhertu — Gastric/GEJ25%

White Space Opportunity

342

Doctors on 1 brand only

Tagrisso Only

214

Enhertu not started

Enhertu Only

128

Tagrisso not started

Dual Brand Prescribers

204

↑ 22 this quarter

Tagrisso only

214

Tagrisso

High-value Tier 1 & 2 doctors active on Tagrisso with zero Enhertu Rx. Primary cross-sell priority for field teams.

Enhertu only

128

Enhertu

Oncologists with HER2+ focus not yet introduced to Tagrisso NSCLC data. Strong scientific case to make.

Both brands

204

Both

Fully activated doctors. Focus on share of wallet, volume deepening, and referral network activation.

No Rx — dormant

701

Dormant

Received engagements but no prescription placed. Barrier investigation needed by field team.

Priority cross-sell list — Tagrisso → Enhertu

Tier 1 & 2 Tagrisso prescribers with zero Enhertu Rx

HCP	Territory	Tagrisso Rx (YTD)	Last Tagrisso Rx	Enhertu Status	Engagements YTD	Priority
Dr. Arjun Kapoor	Delhi NCR	35	Apr 2	Not started	3	High
Dr. Mehul Desai	Ahmedabad	24	Mar 20	Not started	2	High
Dr. Ravi Iyer	Pune	19	Mar 30	Not started	4	Medium

YTD Actual Patients

804

vs 930 planned (Q1)

YTD Compounded Gap

–126

Carried into Apr target

Territories on Track

5/8

↑ 1 vs last month

Apr Revised Target

328

Base 265 + 63 compounded

Monthly plan vs actual — 2025

Month	Target	Actual	Achievement	Gap	Status
January	285	262	92%	–23	Under
February	290	272	94%	–18	Under
March	310	270	87%	–40	Gap
April (MTD)	265	–	–	–	In Progress

Top 10% HCPs drive

58%

of total Rx volume

Top 25% threshold

82%

of NBRX YTD

Gini Coefficient

0.64

High concentration

Move-up candidates

34

Near Tier 2 threshold

Concentration curve — NBRX YTD

1,247 HCPs sorted by Rx volume

Actual curve

Equality line

25% threshold

50% threshold

Total Enrolled Patients

2,841

Active as of Apr 2025

Active on Tagrisso

1,624

↑ 87 vs last month

Active on Enhertu

1,217

↑ 54 vs last month

New Initiations (Apr)

214

↑ 3% MoM

New Initiations — 6 Month Trend

Total Initiations by Brand

Monthly new patient starts — all brands

Tagrisso

Enhertu

Initiations by Zone — Apr 2025

Zone-wise new patient starts

North Zone62

South Zone58

West Zone54

East Zone40

MoM Change by Zone

North↑ +13%

South↑ +12%

West↑ +8%

East↑ +5%

Adherence & Days of Therapy

Adherence Curve — Cohort Survival

% patients still on therapy by cycle number

Tagrisso 82%Enhertu 74%

Zone	Tagrisso	Enhertu	Overall	Trend
North	84%	76%	80%	↑ +2pp
South	86%	79%	82%	↑ +4pp
West	81%	73%	77%	↑ +1pp
East	78%	69%	74%	Flat

DOT Trend — Days of Therapy

Monthly DOT by brand — last 6 months

Tagrisso

Enhertu

Avg Cycles

8.2

per patient

Median Cycles

7

per patient

Programme Breakdown — Indication & Cycle Profile

Enrolments by Indication

Last 6 months — stacked by indication

NSCLC (Tagrisso)

HER2+ Breast

Gastric/GEJ

Cycle Distribution

Patient population by cycle band

Avg Cycles

8.2

Median

7

Max Observed

24

Total Units Dispensed (Apr)

3,847

Paid + FOC combined

Paid Units

2,614

68% of total

FOC Units

1,233

32% of total

FOC Ratio (YTD)

30%

↑ 2pp vs last yr

Paid vs FOC Units — Last 6 Months

Monthly unit trends by type

Paid Units

FOC Units

Monthly Unit Details

Month	Paid Units	FOC Units	Total	FOC %	MoM Growth
November	1,920	620	2,540	24%	–
December	2,040	690	2,730	25%	↑ 7%
January	2,180	780	2,960	26%	↑ 8%
February	2,310	890	3,200	28%	↑ 8%
March	2,490	1,080	3,570	30%	↑ 12%
April	2,614	1,233	3,847	32%	↑ 8%

Forecast Total (H2 2025)

26,800

Paid + FOC units (6 months)

Forecast Paid Units

18,200

↑ 18% vs H1

Forecast FOC Units

8,600

32% projected ratio

Forecast Confidence

87%

Model R² = 0.91

Unit Forecast — Next 6 Months

Actuals + forecasted units with confidence bands

Paid Units (actual)

Paid Units (forecast)

FOC (actual)

FOC (forecast)

6-Month Unit Forecast Summary

Month	Paid Forecast	FOC Forecast	Total Forecast	YoY Growth	Confidence
May 2025	2,760	1,290	4,050	↑ 16%	92%
June 2025	2,890	1,350	4,240	↑ 18%	90%
July 2025	3,020	1,410	4,430	↑ 19%	87%
August 2025	3,100	1,460	4,560	↑ 20%	84%
September 2025	3,200	1,520	4,720	↑ 21%	82%
October 2025	3,230	1,570	4,800	↑ 22%	80%

Accounts Tracked

94

Active of top 100 YTD

Growing Accounts

61

↑ Rx vs prior period

Declining Accounts

18

Needs field attention

Avg Rx / Account (YTD)

32

Top 100 combined

Top Accounts — Rx Evolution

Click any account to view Account Summary

#	Account Name	City / Zone	Tagrisso Rx	Enhertu Rx	Total Rx (YTD)	vs Prior Period	Status
1	Apollo Hospitals — Mumbai	Mumbai / West	112	74	186	↑ +18%	Growing
2	Tata Memorial Centre — Mumbai	Mumbai / West	98	64	162	↑ +14%	Growing
3	AIIMS — Delhi	Delhi / North	90	58	148	↑ +9%	Growing
4	Rajiv Gandhi Cancer Institute	Delhi / North	124	0	124	↑ +5%	Stable
5	Yashoda Hospital — Hyderabad	Hyderabad / South	96	0	96	↓ –12%	Declining
6	Fortis Cancer Institute — Noida	Noida / North	52	36	88	↑ +7%	Growing

Customer 360 ›

AH

Apollo Hospitals — Mumbai

Both Brands Key Account

Tertiary Cancer Centre · 18 oncologists on network · Mumbai West Territory

NSCLC HER2+ Breast Gastric/GEJ KAM: Rohan Verma · Account Since: Jan 2023

Total Rx (YTD)

186

Enrolled Patients

42

Active HCPs

12

Last Interaction

Apr 11

Adoption Across Brands

Share of prescribers per brand at this account

Tagrisso11/18 HCPs

61% prescriber penetration

Enhertu8/18 HCPs

44% prescriber penetration

Non-Sales Engagements (YTD)

Scientific & educational touchpoints

CME / Symposia6

Advisory Board2

Webinars / KOL Talks8

Publication Sharing14

Events — Upcoming & Past

Engagement events tracked at this account

Event	Type	Date	Attendees	Brands Covered	Status
NSCLC Masterclass — Apollo Mumbai	CME	Apr 20, 2025	12 HCPs	Tagrisso	Upcoming
HER2+ Oncology Roundtable	Advisory	Mar 28, 2025	8 HCPs	Enhertu	Completed
Tumour Board Presentation	Scientific	Mar 15, 2025	6 HCPs	Both	Completed

Active Distributors

48

Across 28 cities

Orders in Transit

124

Across all zones

Orders Placed (MTD)

58

↑ 11% vs last month

Delivered (MTD)

216

Confirmed deliveries

Distributor Network Overview

Current stock & status by distributor

Distributor	City / Zone	Tagrisso Stock	Enhertu Stock	Last Order	Alert
Apex Pharma Dist.	Mumbai / West	86 units	42 units	Apr 12	OK
Medline Distributors	Delhi / North	22 units	38 units	Apr 10	Low Stock
CureMax Pharma	Chennai / South	54 units	4 units	Apr 8	Critical
HealthFirst Dist.	Kolkata / East	18 units	14 units	Apr 7	Monitor
Prime Healthcare	Pune / West	68 units	31 units	Apr 13	OK

Order Processing Pipeline

Current order status snapshot

Order Placed58

Processing / WH Pick34

In Transit22

Delivered (MTD)216

Stockout Risk

Distributors flagged for immediate action

CureMax Pharma — Chennai

Enhertu: 4 units · ~2 days cover

Critical

Medline Distributors — Delhi

Tagrisso: 22 units · ~5 days cover

Low Stock

HealthFirst Dist. — Kolkata

Both brands below reorder point

Monitor

Secondary Sales (Apr)

₹18.4 Cr

Trade channel MTD

Tagrisso Secondary

₹11.2 Cr

↑ 14% MoM

Enhertu Secondary

₹7.2 Cr

↑ 11% MoM

Secondary vs Primary

98%

Channel equilibrium

Secondary Sales Trend by HQ

Monthly trend by headquarter / territory

HQ / Territory	Nov	Dec	Jan	Feb	Mar	Apr	MoM
Mumbai North	₹2.8 Cr	₹3.1 Cr	₹3.4 Cr	₹3.6 Cr	₹3.9 Cr	₹4.2 Cr	↑ 8%
Delhi NCR	₹2.4 Cr	₹2.6 Cr	₹2.9 Cr	₹3.1 Cr	₹3.3 Cr	₹3.6 Cr	↑ 9%
Hyderabad	₹1.8 Cr	₹2.0 Cr	₹2.2 Cr	₹2.4 Cr	₹2.5 Cr	₹2.7 Cr	↑ 8%
Chennai	₹1.6 Cr	₹1.7 Cr	₹1.9 Cr	₹2.0 Cr	₹2.1 Cr	₹2.3 Cr	↑ 10%
Kolkata	₹1.2 Cr	₹1.3 Cr	₹1.4 Cr	₹1.4 Cr	₹1.4 Cr	₹1.4 Cr	Flat

Total Closing Stock

2,840

Units across all distributors

Tagrisso Stock

1,720

~14 days coverage

Enhertu Stock

1,120

~12 days coverage

Overstocked (>45d cover)

4

Distributors to review

Distributor Closing Stock & Inventory Trend

Monthly closing stock levels

Tagrisso

Enhertu

Distributor-wise Inventory Status

Distributor	Tagrisso Closing	Enhertu Closing	Days Cover	Stock Trend	Status
Apex Pharma Dist.	420	280	16d	↑ Building	OK
Medline Distributors	380	240	14d	Stable	OK
CureMax Pharma	280	60	7d	↓ Depleting	Critical
HealthFirst Dist.	220	160	10d	Stable	Watch

Projected Demand (May)

3,180

Units across both brands

Current Network Stock

1,560

↓ Below 60-day cover

Demand vs Supply Balance — May to Oct 2025

Projected Demand vs Available Stock

6-month forward view · both brands combined

Projected Demand

Available Stock

Gap / Shortfall

SKU-Level Demand Plan

Brand · pack · forecast vs current stock

SKU	May Demand	Jun Demand	Network Stock	Days Cover
Tagrisso 80mg — 30T	1,840	1,960	1,620	26d
Tagrisso 40mg — 30T	480	510	280	17d
Enhertu 100mg — Vial	620	650	180	8d
Enhertu 160mg — Vial	240	260	310	38d

Zone-Level Coverage Assessment

Inventory Coverage by Zone — May 2025

Stock days cover vs minimum 30-day threshold

Zone	Tagrisso Stock	TG Days Cover	Enhertu Stock	ENH Days Cover
North Zone	620 units	38d	82 units	21d
South Zone	540 units	34d	110 units	32d
West Zone	280 units	19d	38 units	9d
East Zone	380 units	31d	64 units	18d

Forecast Secondary (May)

₹20.1 Cr

Next month projection

Model Accuracy (MAE)

3.2%

Mean absolute error

6M Forecast Total

₹130.5 Cr

↑ 22% vs prior 6M

Peak Month

Oct 2025

₹25.4 Cr projected

Secondary Forecast — Next 6 Months

Actuals + model forecast based on PAP trajectory & current secondary trend

Actual Secondary

Forecast

6-Month Secondary Forecast Summary

Month	Tagrisso Forecast	Enhertu Forecast	Total Forecast	MoM Growth
May 2025	₹12.4 Cr	₹7.7 Cr	₹20.1 Cr	↑ 9%
Jun 2025	₹13.1 Cr	₹8.2 Cr	₹21.3 Cr	↑ 6%
Jul 2025	₹13.8 Cr	₹8.6 Cr	₹22.4 Cr	↑ 5%
Aug 2025	₹14.4 Cr	₹9.0 Cr	₹23.4 Cr	↑ 4%
Sep 2025	₹14.9 Cr	₹9.4 Cr	₹24.3 Cr	↑ 4%
Oct 2025	₹15.6 Cr	₹9.8 Cr	₹25.4 Cr	↑ 5%

Tagrisso Market Share

42%

NSCLC EGFR+ · Q1 2025

Enhertu Market Share

28%

HER2+ Breast/Gastric

Tagrisso Growth (YoY)

+22%

8pp ahead of market

Enhertu Growth (YoY)

+31%

17pp ahead of market

Value Share Evolution — IPSOS

Tagrisso — Market Share Trend (NSCLC)

Quarterly · IPSOS syndicated data

Tagrisso

Lead Competitor

Competitive Share — NSCLC Q1 2025

IPSOS syndicated data

Tagrisso (AZ)

42%

Competitor A

30%

Competitor B

20%

Others

8%

Volume Share & Market vs Product Growth

Volume Share Evolution — Quarterly

IPSOS volume data · all brands

Quarter	Tagrisso Units	TG Share	Enhertu Units	ENH Share	AZ Combined
Q2 2024	14,200	34%	7,400	18%	52%
Q3 2024	15,800	36%	8,200	19%	55%
Q4 2024	16,900	37%	9,400	21%	58%
Q1 2025	18,200	38%	11,600	24%	62%

Market Growth vs Product Growth

Quarterly YoY growth · IPSOS

Tagrisso

Enhertu

Market Avg

Market

+14%

Tagrisso

+22%

Enhertu

+31%

Tagrisso Net Price/Unit

₹1.42L

Apr 2025 net realized

Enhertu Net Price/Unit

₹2.18L

Apr 2025 net realized

Price Premium vs Comp.

+8%

Tagrisso vs nearest comp.

Price Index

1.08

vs competitor average

Competitive Price Analytics — NSCLC

Net price per treatment cycle comparison

Brand	Company	Indication	List Price	Net Realized	vs Tagrisso	Price Trend
Tagrisso 80mg	AstraZeneca	NSCLC EGFR+	₹1.58L	₹1.42L	—	Stable
Gefitinib 250mg	Competitor	NSCLC EGFR+	₹0.68L	₹0.62L	–56%	↓ Declining
Erlotinib 150mg	Competitor	NSCLC EGFR+	₹0.72L	₹0.65L	–54%	Stable
Afatinib 40mg	Competitor	NSCLC EGFR+	₹1.24L	₹1.12L	–21%	↑ Rising

Competitive Price Analytics — HER2+

Enhertu vs competitive landscape

Brand	Company	Indication	List Price	Net Realized	vs Enhertu	Price Trend
Enhertu 5.4mg/kg	AZ / Daiichi	HER2+ Breast	₹2.42L	₹2.18L	—	Stable
Trastuzumab	Competitor	HER2+ Breast	₹0.92L	₹0.82L	–62%	↓ Declining
Pertuzumab	Competitor	HER2+ Breast	₹1.84L	₹1.66L	–24%	Stable

IB Total Revenue (YTD)

₹8.4 Cr

Institutional channel

Tagrisso IB Rx (YTD)

1,942

↑ 16% YoY

Enhertu IB Rx (YTD)

1,342

↑ 28% YoY

Active IB Accounts

84

7 new this quarter

Rx Evolution & Account Performance

IB Rx Trend — Monthly

Institutional Rx volume by brand

Tagrisso IB

Enhertu IB

Top IB Accounts — Sales & Volume

YTD comparison · top 5 accounts

Account	TG Vol.	ENH Vol.	Revenue YTD	YoY	Status
Tata Memorial	210	132	₹2.1 Cr	↑ 24%	Key
AIIMS Delhi	188	114	₹1.8 Cr	↑ 18%	Key
Apollo Cancer	142	98	₹1.4 Cr	↑ 22%	Key
Manipal Hosp.	118	84	₹1.1 Cr	↑ 8%	Stable
RGCI Delhi	96	62	₹0.9 Cr	↓ –4%	Declining

6-Month Sales Waterfall Forecast

Sales Bridge — Apr 2025 → Oct 2025

IB channel growth drivers & risks

Account-Level 6M Prediction

Monthly revenue forecast per key IB account

Account	Apr Actual	May	Jun	Jul	Aug–Oct	6M CAGR
Tata Memorial Centre	₹2.1 Cr	₹2.3 Cr	₹2.4 Cr	₹2.6 Cr	₹2.7–3.0 Cr	↑ 7%/mo
AIIMS Delhi	₹1.8 Cr	₹2.0 Cr	₹2.1 Cr	₹2.2 Cr	₹2.3–2.5 Cr	↑ 6%/mo
Apollo Cancer Centre	₹1.4 Cr	₹1.5 Cr	₹1.6 Cr	₹1.7 Cr	₹1.8–2.0 Cr	↑ 6%/mo

HCP Performance Report

NBRX, territory, tier data

Territory

Period

PAP Analytics Report

Adherence, DOT, units data

Indication

Period

Market Intelligence Report

Share, competitive landscape

Region

Quarter

Recent Downloads

Last 10 generated reports

Report Name	Type	Generated By	Date
HCP_Performance_Apr2025.xlsx	HCP Performance	User A	Apr 10, 2025
PAP_Analytics_Mar2025.xlsx	PAP Report	User B	Apr 8, 2025
Market_Intelligence_Q1.xlsx	Market Share	User C	Apr 6, 2025

Upload your data files to power analytics and insights. Supported formats: Excel (.xlsx), CSV. Files are processed securely and validated automatically.

HCP Master Data

Veeva CRM database export

Required

Drop file here or click to browse

Excel or CSV · Max 50MB

Last uploaded: Apr 1, 2025

PAP Programme Data

Patient enrolment and adherence data

Required

Drop file here or click to browse

Excel or CSV · Max 50MB

Last uploaded: Apr 5, 2025

Secondary Sales / Distribution

Distributor secondary and stock data

Required

Drop file here or click to browse

Excel or CSV · Max 50MB

Last uploaded: Apr 3, 2025

IPSOS Market Intelligence

Market share & competitive data

Optional

Drop file here or click to browse

Excel or CSV · Max 50MB

Last uploaded: Apr 2, 2025

Showing data for Tagrisso · South Zone only. Contact your admin to update access.

My NBRX (Apr)

58

↑ 12% vs Mar

Plan Achievement

94%

vs Apr target

Active HCPs

42

↑ 4 this month

PAP Patients (My Zone)

218

↑ 14 MoM

NBRX vs Target — Weekly

Tagrisso · South Zone · Apr 2025

HCP Coverage Summary

South Zone · this month

Tier 1 — Visited18/22

Tier 2 — Visited14/24

Tier 3 — Visited9/28

Total Calls

84

Missed

13

My Top Accounts — Apr Rx

South Zone · Tagrisso

Account	City	Apr Rx	Mar Rx	MoM	Status
Apollo Hospitals, Chennai	Chennai	18	14	↑ 29%	Growing
MIOT International	Chennai	12	11	↑ 9%	Growing
Gleneagles Health City	Chennai	10	12	↓ –17%	Declining
Narayana Health, Bangalore	Bangalore	9	8	↑ 13%	Stable

HCPs in My Territory

74

South Zone · Tagrisso

Total Planned

172

Calls · Apr 2025

Total Leads

89

↑ 11 vs Mar

Total Actuals

61

Rx written this month

By Indication — Planned, Leads & Actuals

NSCLC (Tagrisso)

South Zone · Apr 2025

55

Top HCPs by Leads

Dr. Meera Krishnan

13

Dr. Rajan Pillai

11

Dr. Priya Venkat

8

Dr. Asha Nair

6

Planned, Leads & Actuals

Planned110

Leads55

50.0%

Actuals38

34.5%

Leads by Segment

Tier A 69% Tier B 16% Tier C 10% Others 5%

HCC & Other (Enhertu)

South Zone · Apr 2025

34

Top HCPs by Leads

Dr. Rajan Pillai

8

Dr. Meera Krishnan

6

Dr. Suresh Babu

4

Dr. Priya Venkat

3

Planned, Leads & Actuals

Planned62

Leads34

54.8%

Actuals23

37.1%

Leads by Segment

HER2+ 59% Gastric 20% Other 18% DG02 3%

HCP-wise Planned, Leads & Actuals

Apr 2025 · South Zone · all indications

HCP Name	HQ	Tier	Indication	Planned	Leads	Actuals (Rx)	Conversion
Dr. Meera Krishnan	Chennai	T1	NSCLC	16	13	11	85%
Dr. Rajan Pillai	Chennai	T1	HER2+	14	11	8	73%
Dr. Priya Venkat	Bangalore	T2	NSCLC	10	8	6	75%
Dr. Asha Nair	Chennai	T2	NSCLC	8	6	4	67%
Dr. Suresh Babu	Bangalore	T2	HER2+	8	4	2	50%
Dr. Vinod Kumar	Hyderabad	T3	NSCLC	6	4	3	75%

HOPM (Apr)

9

vs 20 planned · 45% exec

Sponsorships

8

↑ 2 vs Mar

Medical Engagements

3

Sessions at onco update

Other Activities

5

Plain sponsorship + others

Activity data synced from Veeva CRM · Last sync: Today 8:30 AM

HOPM Planned vs Executed — Monthly

South Zone · Jan to Apr 2025

Planned

Executed

Activity by Type

Apr 2025 · South Zone

HOPM9 (36%)

Sponsorship8 (32%)

Medical Engagement3 (12%)

Plain Sponsorship3 (12%)

Others2 (8%)

HQ-wise Totals

Chennai15

Bangalore7

Hyderabad3

Activity Log — Apr 2025

All field activities · South Zone · from Veeva

Date	MKA	HQ	HCP	Hospital	Activity Type	Planned	Implemented	HOPM Planned	HOPM Exec
Apr 15	Rajesh S.	Chennai	Dr. Meera Krishnan	Apollo Chennai	Session at Onco	Yes	Yes	1	1
Apr 14	Rajesh S.	Chennai	Dr. Rajan Pillai	MIOT International	Sponsorship	Yes	Yes	0	0
Apr 13	Rajesh S.	Bangalore	Dr. Priya Venkat	Narayana Health	Plain Sponsorship	Yes	No	1	0
Apr 12	Rajesh S.	Chennai	Dr. Asha Nair	Aagam Hospital	Session at Onco	Yes	Yes	0	0
Apr 10	Rajesh S.	Hyderabad	Dr. Vinod Kumar	Yashoda Hospital	HOPM	Yes	No	1	0

Area Secondary (Apr)

₹3.2 Cr

↑ 11% vs Mar

NBRX — Area Total

58

↑ 12% MoM

Plan Achievement

94%

vs Apr target

PAP Initiations (Apr)

22

↑ 3 vs Mar

Monthly Overall — Nov to Apr

Area NBRX Trend

Tagrisso · South Zone · monthly actuals vs target

Monthly Summary Table

South Zone · Tagrisso · Nov–Apr

Month	NBRX Target	NBRX Actual	Achievement	Secondary	PAP Initiations	vs Plan
Nov 2024	42	38	90%	₹2.2 Cr	12	Below
Dec 2024	44	43	98%	₹2.4 Cr	15	On Plan
Jan 2025	46	48	104%	₹2.6 Cr	17	Above
Feb 2025	50	52	104%	₹2.8 Cr	19	Above
Mar 2025	54	55	102%	₹2.9 Cr	19	Above
Apr 2025	62	58	94%	₹3.2 Cr	22	Close

Total Sales (Apr)

₹3.2 Cr

↑ 11% vs Mar

GI Sales (Apr)

₹2.6 Cr

Tagrisso GI channel

Total Accounts

18

South Zone active

Total Units

312

↑ 8% MoM

Sales & GI Sales Trend

Monthly total vs GI units · Nov to Apr

Total Units

GI Units

Account Sales — GI vs Remaining

Units · South Zone · Apr 2025

Apollo, Chennai66

MIOT International48

Narayana Health42

Gleneagles36

Vijaya Hospital26

GI Units

Remaining

MKA-wise Summary — Account Sales

Units · Total Sales · GI Units · GI Sales · South Zone

MKA	Account	TA	Units	Total Sales	GI Units	GI Sales	MoM
Rajesh S.	Apollo, Chennai	NSCLC	66	₹82L	52	₹65L	↑ 15%
Rajesh S.	MIOT International	NSCLC	48	₹64L	36	₹48L	↑ 10%
Rajesh S.	Narayana Health	NSCLC	42	₹52L	30	₹37L	↑ 11%
Rajesh S.	Gleneagles	NSCLC	36	₹48L	21	₹28L	↓ –20%
Rajesh S.	Vijaya Hospital	NSCLC	26	₹38L	16	₹23L	↑ 6%
Total			218	₹2.84 Cr	155	₹2.01 Cr	—

My PAP Patients

218

Tagrisso · South Zone · active

New Initiations (Apr)

22

↑ 3 vs Mar

Total Leads (Apr)

31

NSCLC + other indications

Lead Conversion

71%

↑ 8pp vs Mar

Indication-wise Weekly Leads vs Actuals

NSCLC — Weekly Leads vs Actuals

Tagrisso · South Zone · Apr 2025

Leads

Actuals

HCC & Other — Weekly Leads vs Actuals

South Zone · Apr 2025

Leads

Actuals

Initiations — Monthly Trend

Monthly Initiations — My Zone

Tagrisso · South Zone · Nov to Apr

Initiations by Account — Apr

New patient starts at each account

Apollo Hospitals, Chennai7

MIOT International5

Narayana Health, Blr4

Gleneagles3

Vijaya Hospital3

Weekly Tracker — Leads by MKA & HQ

South Zone · Tagrisso · Apr 2025 · all indications

MKA	HQ	Week	NSCLC Leads	NSCLC Actuals	HCC Leads	HCC Actuals	Total Leads
Rajesh S.	Chennai	Wk 1	6	5	3	2	9
Rajesh S.	Chennai	Wk 2	8	7	4	3	12
Rajesh S.	Chennai	Wk 3	10	9	5	4	15
Rajesh S.	Chennai	Wk 4	13	11	6	5	19
Total — Apr 2025			37	32	18	14	55

Avg Cycles — My Zone

7.4

Per enrolled patient

Median Cycles

7

South Zone Tagrisso

Longest Ongoing

18

Cycles · 1 patient

Cycle Distribution & Patient Summary

Cycle Distribution — My Patients

Patient count by cycle band

Avg Cycles

7.4

Median

7

Max Observed

18

Patient-level Cycle Summary

South Zone · Tagrisso · active patients on 8+ cycles

Patient ID	Account	Cycles Completed	Last Supply	Next Supply Due	Adherence
TG-SZ-0214	Apollo, Chennai	18	Apr 10	May 10	91%
TG-SZ-0388	MIOT International	14	Apr 8	May 8	87%
TG-SZ-0452	Narayana Health	11	Apr 6	May 6	82%
TG-SZ-0571	Apollo, Chennai	9	Apr 12	May 12	76%
TG-SZ-0634	Vijaya Hospital	8	Apr 3	May 3	73%

Total Units Dispensed (Apr)

218

South Zone · Tagrisso

Paid Units

162

↑ 9% MoM

FOC Units

56

Free-of-charge supply

FOC Ratio

26%

of total dispensed

Paid vs FOC Trend — Nov to Apr

Paid & FOC Units — Monthly Trend

South Zone · Tagrisso · last 6 months

Paid

FOC

Paid & FOC by Account — Apr

Unit split per account · South Zone

Account	Paid Units	FOC Units	Total	FOC %	vs Mar
Apollo Hospitals, Chennai	52	14	66	21%	↑ 12%
MIOT International	38	10	48	21%	↑ 9%
Narayana Health, Blr	32	10	42	24%	↑ 5%
Gleneagles Health City	24	12	36	33%	↓ –8%
Vijaya Hospital	16	10	26	38%	↑ 4%